{
  "kind": "treatment",
  "slug": "viloxazine-er-qelbree",
  "type": "medication",
  "name": "Viloxazine ER",
  "summary": "Viloxazine ER is a non-stimulant medication used for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.",
  "description": "Viloxazine extended-release (marketed as Qelbree) is a selective norepinephrine reuptake inhibitor (NRI) with additional serotonergic activity, approved for the treatment of ADHD in children, adolescents, and adults. Originally developed as an antidepressant in Europe, viloxazine has been reformulated as an extended-release capsule to provide all-day symptom control. It offers a non-stimulant alternative for patients who do not tolerate or respond to stimulant therapy.",
  "category": "medications/psychiatry",
  "tags": [
    "non-stimulant",
    "ADHD",
    "NRI",
    "extended-release"
  ],
  "metadata": {
    "drug_classes": [
      "Non-stimulant ADHD medication"
    ],
    "therapeutic_categories": [
      "Psychiatry"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription only",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Qelbree"
    ],
    "age_groups": [
      "Pediatric",
      "Adult"
    ],
    "treatment_duration": [
      "Long-term maintenance"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Pediatric psychiatry"
    ],
    "fda_approval_year": 2021
  },
  "clinical_metadata": {
    "primary_indications": [
      "ADHD"
    ],
    "off_label_uses": [
      "Depression",
      "Anxiety disorders"
    ],
    "contraindications": [
      "Use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI",
      "Hypersensitivity to viloxazine or formulation components"
    ],
    "monitoring_required": [
      "Blood pressure and heart rate",
      "Mood changes or suicidal ideation",
      "Sleep patterns"
    ],
    "efficacy_rating": {
      "ADHD": 2
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "viloxazine",
      "Qelbree",
      "non-stimulant ADHD medication"
    ],
    "synonyms": [
      "viloxazine hydrochloride ER",
      "Qelbree capsules"
    ],
    "common_misspellings": [
      "viloxacin",
      "viloxizine",
      "viloxazene"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Treatment of ADHD in patients 6 years and older"
      ]
    },
    {
      "type": "mechanism",
      "text": "Selective norepinephrine reuptake inhibitor with additional serotonergic modulation, increasing norepinephrine and serotonin availability in the brain."
    },
    {
      "type": "dosing",
      "adult": {
        "oral": "Start at 200 mg once daily; may increase by 200 mg weekly as tolerated to a maximum of 600 mg once daily."
      },
      "pediatric": {
        "oral": "Ages 6–11: Start at 100 mg once daily; may increase by 100 mg weekly to a maximum of 400 mg once daily. Ages 12–17: Start at 200 mg once daily; may increase by 200 mg weekly to a maximum of 400 mg once daily."
      }
    },
    {
      "type": "dosage_forms",
      "items": [
        "Extended-release capsules: 100 mg, 150 mg, 200 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Symptom improvement may be observed within 1–2 weeks; full therapeutic effect may take up to 6–8 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "somnolence",
        "fatigue",
        "decreased appetite",
        "irritability",
        "insomnia",
        "nausea",
        "vomiting"
      ],
      "less_common": [
        "tachycardia",
        "anxiety",
        "weight loss"
      ],
      "serious": [
        "suicidal thoughts and behaviors",
        "severe allergic reactions",
        "marked increases in blood pressure or heart rate"
      ]
    },
    {
      "type": "warnings",
      "other": [
        "May increase risk of suicidal thoughts and behaviors in children, adolescents, and young adults",
        "Monitor blood pressure and heart rate regularly",
        "Avoid abrupt discontinuation without medical guidance"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Hypertensive crisis or serotonin syndrome",
          "action": "Contraindicated; allow 14-day washout"
        },
        {
          "with": "CYP1A2 inhibitors",
          "risk": "Increased viloxazine levels",
          "action": "Monitor and adjust dose as needed"
        },
        {
          "with": "Drugs that increase blood pressure",
          "risk": "Additive hypertensive effects",
          "action": "Monitor closely"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "ADHD symptom control",
        "Blood pressure and heart rate",
        "Mood and suicidal ideation"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Limited human data; use only if potential benefit outweighs risks",
      "lactation": "Unknown excretion in human milk; use caution",
      "geriatrics": "Limited data; monitor cardiovascular status"
    },
    {
      "type": "tapering",
      "text": "Gradually reduce dose to minimize withdrawal or rebound symptoms."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Non-stimulant option for ADHD, useful in patients with stimulant intolerance or substance misuse concerns",
        "May cause somnolence, especially early in treatment",
        "Extended-release formulation allows once-daily dosing"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Qelbree Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "NHS - Viloxazine",
          "url": "https://www.nhs.uk/medicines/viloxazine/"
        },
        {
          "label": "PubChem - Viloxazine",
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Viloxazine"
        }
      ]
    }
  ],
  "seo": {
    "title": "Viloxazine ER (Qelbree) - Uses, Dosage, Side Effects, and Warnings",
    "description": "Viloxazine ER (Qelbree) is a non-stimulant ADHD medication. Learn about dosing, side effects, interactions, and monitoring."
  }
}
